The GYPC Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with disrupted expression of glycophorin C. This ready-to-use pool of gene-edited human lung adenocarcinoma cells saves researchers the effort of knockout generation and isolation. As a heterogeneous population, the polyclonal format provides a robust model for loss-of-function studies. The CRISPR/Cas9-mediated disruption allows investigation of GYPC functions in a non-erythroid context, particularly in pathways governing cell adhesion, migration, and cytoskeletal organization.
The host cell line, NCI-H1975, is a human non-small cell lung adenocarcinoma model derived from a non-smoker female. It harbors activating EGFR L858R and T790M mutations, making it a clinically relevant system for lung cancer research and drug resistance studies. These epithelial cells are widely used to study tumorigenesis, metastasis, and therapeutic response. Using NCI-H1975 as the host explores non-canonical roles of GYPC in cancer, where erythroid membrane proteins may affect tumor progression and metastatic dissemination.
Glycophorin C (GYPC) links the plasma membrane to the spectrin-actin cytoskeleton via protein 4.1 (EPB41) and p55 (MPP1). This complex, including spectrin (SPTA1/SPTB) and actin, maintains erythrocyte shape and is a receptor for Plasmodium falciparum EBA-140. Transcriptional regulation involves GATA1 and KLF1. While traditionally studied in red cells, GYPC and its partners may affect epithelial cell morphology, adhesion, and motility. The knockout in NCI-H1975 disrupts this axis, enabling study of its role in lung cancer behavior.
Knockout of GYPC in NCI-H1975 creates a significant model to explore glycophorin C??s potential role in cancer. Despite extensive characterization in erythrocytes, its function in epithelial cells is poorly understood. This polyclonal knockout population enables investigation of GYPC??s contribution to adhesion, migration, and invasion??processes central to metastasis. In the context of EGFR-mutant lung adenocarcinoma, disrupting membrane-cytoskeletal linkages may reveal how cortical actin organization and binding partner localization influence tumor cell aggressiveness. The polyclonal format minimizes clonal artifacts and enhances assay reproducibility.
This polyclonal knockout product supports diverse functional assays. Western blotting and immunofluorescence confirm GYPC loss and assess proteins like EPB41 and MPP1. Flow cytometry quantifies surface markers and cell cycle changes. Adhesion and transwell migration/invasion assays measure metastatic potential, while phalloidin staining visualizes actin cytoskeletal alterations. The model can also be used for malaria invasion studies via GYPC reconstitution or for drug screening targeting cytoskeletal dynamics in EGFR-mutant lung cancer. For further information, please contact Ascent Research.
